Share this article
Share this article
PROVIDENCE, R.I., March 31, 2021 /PRNewswire/ Ximedica today announced a partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the Defense Advanced Research Projects Agency s (DARPA) Nucleic Acids On-Demand World-Wide (NOW) Program. Integrating Moderna s proprietary mRNA technology with Ximedica s instrument design and engineering expertise, both teams will work closely together in an effort to meet capability expectations set out by the DARPA program over the 4-year partnership. As part of the agreement, Ximedica will receive up to $11 million in funding.
DARPA s Nucleic Acids On-Demand World-Wide initiative aims to develop a mobile, just-in-time manufacturing platform that quickly diagnoses pathogen threats and provides medical countermeasures to deliver pandemic prevention treatments in-field. The resulting Good Manufacturing Practice (GMP) quality mRN
Ximedica announces partnership with Moderna, Inc (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.